Novavax Q2 Profit Down

Novavax (NVAX) reported a significant year-over-year decline in Q2 FY2025 financial results, with net income falling to $107 million ($0.62/share) and net sales to $239 million, primarily attributed to the absence of large recurring revenue streams from the prior year, despite including a $175 million Nuvaxovid BLA approval milestone. The company also raised its full-year 2025 research and development and selling, general and administrative expense guidance to $495-$545 million. Despite these financial declines and increased expense outlook, NVAX shares traded 12.19% higher on the NasdaqGS.

Analysis

Novavax (NVAX) reported a significant year-over-year contraction in its Q2 FY2025 results, with net sales declining to $239 million from $415 million and net income falling to $107 million from $162 million. The revenue shortfall is primarily attributed to the absence of large, recurring revenue streams that benefited the prior-year period. A critical detail is that a substantial portion of the current quarter's revenue, $175 million, stemmed from a one-time milestone payment for the Nuvaxovid BLA approval, which masks even weaker underlying product sales compared to 2024. Compounding the top-line pressure, the company raised its full-year 2025 expense guidance for combined R&D and SG&A to between $495 million and $545 million, signaling escalating operating costs. Despite these challenging fundamental indicators, the market reacted with significant bullishness, driving the stock up 12.19%. This sharp divergence suggests investors may be looking past the historical decline and focusing on the strategic value of the BLA approval or that the results, while poor, surpassed deeply negative expectations.

Key Decisions for Investors

• Investors should scrutinize the sustainability of the company's revenue model, as Q2 results were heavily dependent on a one-time $175 million payment, and recurring revenue streams have diminished.
• The upward revision of full-year expense guidance warrants close monitoring of the company's cash burn rate and the strategic rationale behind the increased spending.
• The significant 12.19% stock price increase in the face of declining financials indicates a market disconnect that could present either a valuation risk or an opportunity; understanding the drivers behind this positive sentiment is key.